VEA
DAWN

Virtus ETF Advisers’s Day One Biopharmaceuticals DAWN Stock Holding History

Virtus ETF Advisers’s Portfolio DAWN Stock Details DAWN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$240K Hold
11,200
– – 0.11% 206
2025
Q4 		$104K Buy
+11,200
New +$93.6K 0.05% 326
2025
Q1 		– Sell
-27,296
Closed -$346K – 524
2024
Q4 		$346K Buy
27,296
+1,805
+7% +$25.1K 0.14% 205
2024
Q3 		$355K Hold
25,491
– – 0.17% 214
2024
Q2 		$351K Buy
25,491
+19,413
+319% +$284K 0.17% 198
2024
Q1 		$100K Sell
6,078
-414
-6% -$6.2K 0.05% 363
2023
Q4 		$94.8K Sell
6,492
-847
-12% -$10.3K 0.06% 384
2023
Q3 		$90K Sell
7,339
-734
-9% -$9.57K 0.05% 348
2023
Q2 		$96.4K Buy
8,073
+3,388
+72% +$44.2K 0.06% 401
2023
Q1 		$62.6K Sell
4,685
-1,797
-28% -$35.1K 0.03% 421
2022
Q4 		$139K Sell
6,482
-119
-2% -$2.44K 0.07% 367
2022
Q3 		$132K Buy
6,601
+50
+0.8% +$1.06K 0.05% 375
2022
Q2 		$117K Sell
6,551
-2,335
-26% -$24.1K 0.04% 391
2022
Q1 		$88K Sell
8,886
-527
-6% -$6.96K 0.04% 320
2021
Q4 		$159K Buy
+9,413
New +$193K 0.06% 327

Other funds holding DAWN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
KC
Kryger Capital London, United Kingdom $1.41B AUM 86.31% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
AA
AQR Arbitrage Greenwich, Connecticut $6.09B AUM 27.01% 1-Year Est. Return

Virtus ETF Advisers's DAWN Position: Q1 2026 in Review

Virtus ETF Advisers held its Day One Biopharmaceuticals (DAWN) position steady in Q1 2026 at 11,200 shares worth $240K. The position accounts for 0.11% of the portfolio, ranked #206.

Virtus ETF Advisers first reported a position in DAWN in Q4 2021 and has held it in 15 quarters since. The position peaked at $355K in Q3 2024. 206 funds tracked by Wall St. Rank hold DAWN as of Q1 2026.

  • Virtus ETF Advisers held 11,200 shares of Day One Biopharmaceuticals worth $240K as of Q1 2026.
  • Virtus ETF Advisers left its Day One Biopharmaceuticals share count unchanged in Q1 2026.
  • Day One Biopharmaceuticals made up 0.11% of Virtus ETF Advisers's portfolio in Q1 2026, its #206 holding.
  • Virtus ETF Advisers first reported a position in Day One Biopharmaceuticals in Q4 2021 and has held it in 15 quarters since.
  • Virtus ETF Advisers's Day One Biopharmaceuticals position peaked at $355K in Q3 2024.
  • 206 funds tracked by Wall St. Rank held Day One Biopharmaceuticals as of Q1 2026.

Based on Virtus ETF Advisers's 13F filing for Q1 2026, filed 14 May 2026.